INTERVEXION THERAPEUTICS
InterveXion is a privately-held clinical-stage biopharmaceutical company developing novel product candidates for the treatment of addiction disorders. Their lead clinical asset is IXT-m200, a monoclonal antibody directed against methamphetamine, which acts by re-partitioning methamphetamine away from its sites of action in the CNS. IXT-m200 has received US FDA Fast Track Designation, and is being studied in an ongoing Phase 2 proof-of-concept study (STAMPOUT; NCT03336866). They are also developing a novel vaccine (IXT-v100) against methamphetamine, which is in Preclinical Development.
INTERVEXION THERAPEUTICS
Industry:
Biopharma Biotechnology Health Care Pharmaceutical
Founded:
2004-01-01
Address:
Little Rock, Arkansas, United States
Country:
United States
Website Url:
http://www.intervexion.com
Total Employee:
51+
Status:
Active
Contact:
501.554.2377
Total Funding:
52.8 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API WordPress Mobile Non Scaleable Content Sitelinks Search Box Organization Schema Yoast WordPress SEO Plugin Yoast SEO Premium Yoast Plugins
Similar Organizations
Adrenomed
Adrenomed is a privately-financed, clinical-stage biopharmaceutical company.
Arbutus Biopharma
Arbutus Biopharma Corporation is a publicly-traded biopharmaceutical company.
Ascentage Pharma
Ascentage is a clinical-stage biopharmaceutical company that develops drugs for the treatment of cancer.
Cerebral Therapeutics
Cerebral Therapeutics is a clinical-stage pharmaceutical company.
Context Therapeutics
Context Therapeutics is a clinical-stage biopharmaceutical company.
Corvus Pharmaceuticals
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company.
Enteris BioPharma
Enteris BioPharma is a privately held, clinical stage biopharmaceutical company
Inversago Pharma
Inversago Pharma is a specialized, preclinical-stage biotech company.
Minerva Neuroscience
Minerva Neurosciences is a clinical-stage biopharmaceutical company
Ocugen
Ocugen is a clinical stage biopharmaceutical company.
UNION therapeutics A/S
UNION therapeutics A/S is a privately held, clinical stage, pharmaceutical company.
Current Employees Featured
Founder
Investors List
National Institutes of Health
National Institutes of Health investment in Grant - InterveXion Therapeutics
National Institutes of Health
National Institutes of Health investment in Grant - InterveXion Therapeutics
National Institute on Drug Abuse (NIDA)
National Institute on Drug Abuse (NIDA) investment in Grant - InterveXion Therapeutics
National Institute on Drug Abuse (NIDA)
National Institute on Drug Abuse (NIDA) investment in Grant - InterveXion Therapeutics
National Institutes of Health
National Institutes of Health investment in Grant - InterveXion Therapeutics
National Institutes of Health
National Institutes of Health investment in Grant - InterveXion Therapeutics
National Institute on Drug Abuse (NIDA)
National Institute on Drug Abuse (NIDA) investment in Grant - InterveXion Therapeutics
National Institutes of Health
National Institutes of Health investment in Grant - InterveXion Therapeutics
National Institute on Drug Abuse (NIDA)
National Institute on Drug Abuse (NIDA) investment in Grant - InterveXion Therapeutics
Official Site Inspections
http://www.intervexion.com Semrush global rank: 9.72 M Semrush visits lastest month: 114
- Host name: unalocated.63.wixsite.com
- IP address: 185.230.63.186
- Location: Ashburn United States
- Latitude: 39.018
- Longitude: -77.539
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20147
More informations about "InterveXion Therapeutics"
InterveXion Therapeutics - Crunchbase Company Profile & Funding
InterveXion is a privately-held clinical-stage biopharmaceutical company developing novel product candidates for the treatment of addiction disorders. Their lead clinical asset is IXT-m200, a …See details»
InterveXion Therapeutics - Products, Competitors, Financials, …
InterveXion Therapeutics is a clinical-stage biotechnology company focused on developing therapies for methamphetamine use disorder. Use the CB Insights Platform to explore …See details»
InterveXion Therapeutics - Contacts, Employees, Board Members, …
InterveXion Therapeutics is a privately-held clinical-stage biopharmaceutical companySee details»
InterveXion Therapeutics - Funding, Financials, Valuation & Investors
InterveXion Therapeutics is a privately-held clinical-stage biopharmaceutical companySee details»
InterveXion’s Competitors, Revenue, Number of Employees
InterveXion’s Profile, Revenue and Employees. InterveXion is an Arkansas-based biopharmaceutical company that develops and commercializes novel products for the …See details»
InterveXion - CoBee Company Profile & Funding Rounds
InterveXion is an Arkansas-based biopharmaceutical company that develops and commercializes novel products for the treatment of addiction disorders. Contact Phone: +15015542377See details»
InterveXion Company Profile - Office Locations, Competitors
InterveXion Therapeutics is a biotechnology company developing therapies for substance use disorders. It offers clinical asset IXT-m200, a monoclonal antibody directed against …See details»
(PDF) Profile: InterveXion Therapeutics - ResearchGate
Mar 8, 2017 Operations Director, InterveXion Therapeutics, LLC, Little Rock, AR, USA. 1) How and when did your company start, and where are you. located? InterveXion Therapeutics was …See details»
InterveXion Therapeutics LLC - Drug pipelines, Patents ... - Patsnap
Explore InterveXion Therapeutics LLC with its drug pipeline, therapeutic area, technology platform, 5 clinical trials, 3 news, Drug:Ch-mAb7F9. ... The statistics for drugs in the Pipeline is …See details»
InterveXion Therapeutics - Overview, News & Similar ... - ZoomInfo
Apr 3, 2022 InterveXion's lead product, IXT-m200, is a monoclonal antibody against methamphetamine which has received US FDA Fast Track Designation for treatment of …See details»
InterveXion Therapeutics Stock Price, Funding, Valuation, Revenue ...
Nov 1, 2021 InterveXion Therapeutics has raised $21.9M over 3 rounds. InterveXion Therapeutics's latest funding round was a Grant for $13.8M on November 1, 2021. Date. …See details»
InterveXion Awarded Federal Grant to Fund Phase 2 Study for ...
Oct 4, 2021 LITTLE ROCK, AR, USA, October 4, 2021 / EINPresswire.com / -- InterveXion Therapeutics, a clinical-stage biopharmaceutical company, today announced the award of …See details»
InterveXion to Present Positive Phase 2 STAMPOUT Study Data at …
Apr 4, 2022 LITTLE ROCK, ARKANSAS, USA, April 4, 2022 / EINPresswire.com / -- InterveXion Therapeutics, a private clinical-stage biopharmaceutical company, today announced that it has …See details»
Full article: InterveXion Therapeutics - Taylor & Francis Online
Mar 8, 2017 InterveXion Therapeutics was founded in 2004, based on technology discovered at and licensed from the University of Arkansas for Medical Sciences. We are located in Little …See details»
Grants - InterveXion
InterveXion Awarded Federal Grant to Fund Phase 2 Study for Methamphetamine Use Disorder. Grant fully funds clinical trial, to be called “OUTLAST”, which will initiate in early 2022 LITTLE …See details»
News - InterveXion
Jul 5, 2022 InterveXion to Present Positive Phase 2 STAMPOUT Study Data at Upcoming CPDD Meeting STAMPOUT is the first positive Phase 2 proof-of-concept trial for an anti …See details»
Research programme: anti-methamphetamine therapies
InterveXion is developing monoclonal antibodies (mAbs) for the treatment as well as prevention of substance-related disorders with methamphetamine. The Research programme: anti …See details»
Clinical - InterveXion
Jul 5, 2022 InterveXion Enrolls First Patient in OUTLAST, a Phase 2 Study of IXT-m200 in METH Use Disorder - First clinical trial of an anti-METH antibody in patients seeking treatment …See details»
News | InterveXion
The latest news and updates from InterveXion Therapeutics. top of page. InterveXion Therapeutics, LLC. Home. About. Team. News. More. All Posts; Grants; Clinical; Search. …See details»